Merck (MRK) stock price, revenue, and financials

Merck market cap is $184.4 b, and annual revenue was $47.99 b in FY 2020

$184.4 B

MRK Mkt cap, 15-Sept-2021

$12.1 B

Merck Revenue Q1, 2021
Merck Gross profit (Q1, 2021)8.4 B
Merck Gross profit margin (Q1, 2021), %69.6%
Merck Net income (Q1, 2021)3.2 B
Merck Cash, 31-Mar-20217 B
Merck EV208.6 B
Get notified regarding key financial metrics and revenue changes at MerckLearn more
Banner background

Merck Revenue

Merck revenue was $47.99 b in FY, 2020

Embed Graph

Merck Revenue Breakdown

Embed Graph

Merck revenue breakdown by business segment: 9.4% from Animal Health, 89.1% from Pharmaceutical and 1.5% from Other

Merck revenue breakdown by geographic segment: 6.3% from Asia Pacific (other than Japan and China), 6.8% from China, 5.3% from Latin America, 27.1% from Europe, Middle East and Africa, 43.4% from United States, 7.6% from Japan and 3.4% from Other

Merck Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

40.1b42.3b46.8b48.0b

Revenue growth, %

1%5%11%

Cost of goods sold

12.8b13.5b14.1b15.5b

Gross profit

27.3b28.8b32.7b32.5b

Gross profit Margin, %

68%68%70%68%

R&D expense

10.2b9.8b9.9b13.6b

General and administrative expense

9.8b10.1b10.6b10.5b

Operating expense total

20.1b19.5b20.6b24.0b

Pre tax profit

6.5b8.7b11.5b8.8b

Income tax expense

4.1b2.5b1.7b1.7b

Net Income

2.4b6.2b9.8b7.1b

EPS

0.92.33.8

Merck Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.1b8.0b9.7b8.1b

Accounts Receivable

6.9b7.1b6.8b7.9b

Inventories

5.1b5.4b6.0b6.3b

Current Assets

24.8b25.9b27.5b27.8b

PP&E

12.4b13.3b15.1b18.0b

Goodwill

18.3b18.3b19.4b20.2b

Total Assets

87.9b82.6b84.4b91.6b

Accounts Payable

3.1b3.3b3.7b4.6b

Dividends Payable

1.3b1.5b1.6b1.7b

Short-term debt

3.1b5.3b3.6b6.4b

Current Liabilities

18.6b22.2b22.2b27.3b

Long-term debt

21.4b19.8b22.7b25.4b

Total Debt

24.4b19.8b26.3b31.8b

Total Liabilities

53.3b55.8b58.4b

Common Stock

1.8b1.8b1.8b1.8b

Additional Paid-in Capital

39.9b38.8b39.7b39.6b

Retained Earnings

41.4b42.6b46.6b47.4b

Total Equity

34.6b26.9b26.0b25.4b

Debt to Equity Ratio

0.7 x0.7 x1 x

Debt to Assets Ratio

0.3 x0.2 x0.3 x

Financial Leverage

2.5 x3.1 x3.2 x3.6 x

Merck Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

2.4b6.2b9.8b7.1b

Depreciation and Amortization

4.6b4.5b3.7b1.9b

Accounts Receivable

297.0m(418.0m)294.0m(1.0b)

Inventories

(145.0m)(911.0m)(508.0m)(855.0m)

Accounts Payable

254.0m230.0m399.0m724.0m

Cash From Operating Activities

6.4b10.9b13.4b10.3b

Purchases of PP&E

(4.7b)

Capital Expenditures

(1.9b)(2.6b)(3.5b)

Cash From Investing Activities

2.7b4.3b(2.6b)(9.4b)

Short-term Borrowings

(26.0m)5.1b(3.7b)

Long-term Borrowings

(1.1b)(4.3b)(2.0b)

Dividends Paid

(5.2b)(5.2b)(5.7b)(6.2b)

Cash From Financing Activities

(10.0b)(13.2b)(8.9b)(2.8b)

Net Change in Cash

(423.0m)1.9b2.0b(1.8b)

Free Cash Flow

4.6b8.3b10.0b

Merck Ratios

USDFY, 2017

Revenue/Employee

581.5k

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.5 x

Merck Operating Metrics

FY, 2015FY, 2016FY, 2017May, 2018Nov, 2018FY, 2018FY, 2019Apr, 2020Aug, 2020Nov, 2020

Drugs Approved by FDA

1

Projects in R&D Pipeline

4110

Phase III Trials Products

241820201724242425

Products

309893102

Phase II Trials Products

8141419191932

Trademarks (US)

32

Patent Applications (US)

11

Patents (US)

1

Merck Human Capital

FY, 2019FY, 2018FY, 2017
Male (Board), percent18.3%18.8%18.8%
Male (Senior Management), percent18%19%19%
Female (Board), percent6.1%5.6%5.6%
Female, percent12%12%11.7%
Male, percent12.4%12.4%12.7%
Female (Management), percent10.5%10%9.8%
Female (Senior Management), percent8.8%7.8%7.8%
Male (Management), percent13.9%14.4%14.6%

Merck Employee Rating

4.24819 votes
Culture & Values
4
Work/Life Balance
4
Senior Management
3.6
Salary & Benefits
4.1
Career Opportunities
3.7
Source